Over the last few years, we’ve been battling an array of organic malware attacks from various SARS-CoV-2 variants that have been exploiting a zero-day vulnerability (CVE-2019-05309) in host system immunity. Fortunately, prominent pharma security vendors, such as Pfizer, have made the required software patches available to thwart these attacks using the latest mRNA host cell programming technology.

Read full article on ZDNet